AntimicrobialResearch Phase

Indolicidin

Topical

Overview

Indolicidin is a 13-amino acid antimicrobial peptide derived from bovine neutrophils, characterized by a high tryptophan content (five residues). It exerts antimicrobial activity through multiple mechanisms, including membrane disruption, DNA binding, and inhibition of intracellular processes.

Mechanism of Action

The peptide adopts an extended wedge-shaped conformation that facilitates insertion into lipid bilayers. Indolicidin demonstrates activity against bacteria, fungi, and certain protozoa, though its clinical development has been limited by cytotoxicity..

Research Summary & Key Findings

Preclinical studies in vitro and in murine infection models have demonstrated broad-spectrum antimicrobial activity, including against methicillin-resistant Staphylococcus aureus and Candida species. Structural analogs with reduced mammalian cell toxicity have been synthesized and tested in rodent wound infection models with promising results. No clinical trials in humans have been reported to date, and the peptide remains in the research phase.

Clinical Status

Research Phase

Indolicidin is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Topical

Related Peptides in Antimicrobial

Find a Provider

Find a verified provider who offers Indolicidin therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Indolicidin.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.